Natera Inc. proved to a Delaware federal jury that an Invitae Corp. subsidiary infringed patents related to personalized cancer-monitoring products, earning $19.4 million in damages.
The verdict, which was returned Monday by jurors in the US District Court for the District of Delaware, found that Invitae’s ArcherDX unit infringed each of three patents asserted by Natera and that none of the patents were shown to be invalid.
Though Natera notched a win, the damages number the jury settled on—which covered lost profits and a reasonable royalty for sales of infringing cancer-testing products inside and outside the US—was roughly half ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.